Yangchun Gu
8PUBLICATIONS
16CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Dec 18, 2025
Predictive Value of Patient-Derived Tumor Cell Cluster-Based Drug Sensitivity Assay in Advanced NSCLC.Yangchun Gu, Leilei Yang, Hua Zhang
|Jan 22, 2025
Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer.Zihua Zou, Lige Wu, Xuezhi Hao
|Dec 22, 2021
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.Yuequan Shi, Jian Fang, Chengzhi Zhou
|Dec 01, 2021
Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.Zihua Zou, Xuezhi Hao, Cuiying Zhang
|Nov 29, 2021
Dilemma and solutions of treatment delay in cancer patients during the COVID-19 pandemic: A single-center, prospective survey.Yan'e Liu, Yanhong Yao, Qiqi Wang
Pageof 2
